Fullerene Therapeutics Inc. is ready to take C3
to the next level – clinical trials. We believe a high probability of success in human FDA Phase I clinical trials exists:
- Low likelihood of compound accumulating in humans due to multiple routes of clearance
- The C3 molecule is excreted from the body intact
- C3 compound has a plasma half-life of 8 hours, and has high renal and hepatic clearance
- C3 is not metabolized in mammals
The Company has an active private placement memorandum for investors that meet SEC qualifying regulations. If interested, please contact us for the appropriate paperwork.